Whole-body biodistribution and estimation of radiation-absorbed doses of the dopamine D1 receptor radioligand 11C-NNC 112 in humans

J Nucl Med. 2006 Jan;47(1):100-4.

Abstract

The present study estimated radiation-absorbed doses of the dopamine D(1) receptor radioligand [(11)C]((+)-8-chloro-5-(7-benzofuranyl)-7-hydroxy-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine) (NNC 112) in humans, based on dynamic whole-body PET in healthy subjects.

Methods: Whole-body PET was performed on 7 subjects after injection of 710 +/- 85 MBq of (11)C-NNC 112. Fourteen frames were acquired for a total of 120 min in 7 segments of the body. Regions of interest were drawn on compressed planar images of source organs that could be identified. Radiation dose estimates were calculated from organ residence times using the OLINDA 1.0 program.

Results: The organs with the highest radiation-absorbed doses were the gallbladder, liver, lungs, kidneys, and urinary bladder wall. Biexponential fitting of mean bladder activity demonstrated that 15% of activity was excreted via the urine. With a 2.4-h voiding interval, the effective dose was 5.7 microSv/MBq (21.1 mrem/mCi).

Conclusion: (11)C-NNC 112 displays a favorable radiation dose profile in humans and would allow multiple PET examinations per year to be performed on the same subject.

Publication types

  • Clinical Trial
  • Research Support, N.I.H., Intramural

MeSH terms

  • Adult
  • Benzazepines / pharmacokinetics*
  • Benzofurans / pharmacokinetics*
  • Female
  • Humans
  • Male
  • Metabolic Clearance Rate
  • Organ Specificity
  • Positron-Emission Tomography / methods*
  • Radiation Dosage
  • Radioligand Assay
  • Radiopharmaceuticals / pharmacokinetics
  • Receptors, Dopamine D1 / metabolism*
  • Tissue Distribution
  • Whole Body Imaging / methods*
  • Whole-Body Counting / methods*

Substances

  • Benzazepines
  • Benzofurans
  • Radiopharmaceuticals
  • Receptors, Dopamine D1
  • NNC 112